Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two radiation therapy oncology group prostate clinical trials

George Rodrigues, Kyounghwa Bae, MacK Roach, Colleen Lawton, Bryan Donnelly, David Grignon, Gerald Hanks, Arthur Porter, Herbert Lepor, Howard Sandler

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: To assess ultrahigh (UH; prostate-specific antigen [PSA] levels ≥50 ng/ml) patient outcomes by comparison to other high-risk patient outcomes and to identify outcome predictors. Methods and Materials: Prostate cancer patients (PCP) from two Phase III Radiation Therapy Oncology Group clinical trials (studies 9202 and 9413) were divided into two groups: high-risk patients with and without UH baseline PSA levels. Predictive variables included age, Gleason score, clinical T stage, Karnofsky performance score, and treatment arm. Outcomes included overall survival (OS), distant metastasis (DM), and biochemical failure (BF). Unadjusted and adjusted hazard ratios (HRs) were calculated using either the Cox or Fine and Gray's regression model with associated 95% confidence intervals (CI) and p values. Results: There were 401 patients in the UH PSA group and 1,792 patients in the non-UH PSA PCP group of a total of 2,193 high-risk PCP. PCP with UH PSA were found to have inferior OS (HR, 1.19; 95% CI, 1.02-1.39, p = 0.02), DM (HR, 1.51; 95% CI, 1.19-1.92; p = 0.0006), and BF (HR, 1.50; 95% CI, 1.29-1.73; p < 0.0001) compared to other high-risk PCP. In the UH cohort, PSA level was found to be a significant factor for the risk of DM (HR, 1.01; 95% CI, 1.001-1.02) but not OS and BF. Gleason grades of 8 to 10 were found to consistently predict for poor OS, DM, and BF outcomes (with HR estimates ranging from 1.41-2.36) in both the high-risk cohort and the UH cohort multivariable analyses. Conclusions: UH PSA levels at diagnosis are related to detrimental changes in OS, DM, and BF. All three outcomes can be modeled by various combinations of all predictive variables tested.

Original languageEnglish (US)
Pages (from-to)445-452
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume80
Issue number2
DOIs
StatePublished - Jun 1 2011

Fingerprint

Radiation Oncology
antigens
Prostate-Specific Antigen
Prostate
radiation therapy
Radiotherapy
Clinical Trials
hazards
metastasis
confidence
Prostatic Neoplasms
cancer
Confidence Intervals
Neoplasm Metastasis
intervals
Survival
Neoplasm Grading
regression analysis
grade
Cohort Studies

Keywords

  • Clinical trials
  • External beam radiation therapy
  • Hormonal therapy
  • Outcomes
  • Prognostic factors
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two radiation therapy oncology group prostate clinical trials. / Rodrigues, George; Bae, Kyounghwa; Roach, MacK; Lawton, Colleen; Donnelly, Bryan; Grignon, David; Hanks, Gerald; Porter, Arthur; Lepor, Herbert; Sandler, Howard.

In: International Journal of Radiation Oncology Biology Physics, Vol. 80, No. 2, 01.06.2011, p. 445-452.

Research output: Contribution to journalArticle

Rodrigues, George ; Bae, Kyounghwa ; Roach, MacK ; Lawton, Colleen ; Donnelly, Bryan ; Grignon, David ; Hanks, Gerald ; Porter, Arthur ; Lepor, Herbert ; Sandler, Howard. / Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two radiation therapy oncology group prostate clinical trials. In: International Journal of Radiation Oncology Biology Physics. 2011 ; Vol. 80, No. 2. pp. 445-452.
@article{202d0ecf966046a2b66e06d6a84fbf61,
title = "Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two radiation therapy oncology group prostate clinical trials",
abstract = "Purpose: To assess ultrahigh (UH; prostate-specific antigen [PSA] levels ≥50 ng/ml) patient outcomes by comparison to other high-risk patient outcomes and to identify outcome predictors. Methods and Materials: Prostate cancer patients (PCP) from two Phase III Radiation Therapy Oncology Group clinical trials (studies 9202 and 9413) were divided into two groups: high-risk patients with and without UH baseline PSA levels. Predictive variables included age, Gleason score, clinical T stage, Karnofsky performance score, and treatment arm. Outcomes included overall survival (OS), distant metastasis (DM), and biochemical failure (BF). Unadjusted and adjusted hazard ratios (HRs) were calculated using either the Cox or Fine and Gray's regression model with associated 95{\%} confidence intervals (CI) and p values. Results: There were 401 patients in the UH PSA group and 1,792 patients in the non-UH PSA PCP group of a total of 2,193 high-risk PCP. PCP with UH PSA were found to have inferior OS (HR, 1.19; 95{\%} CI, 1.02-1.39, p = 0.02), DM (HR, 1.51; 95{\%} CI, 1.19-1.92; p = 0.0006), and BF (HR, 1.50; 95{\%} CI, 1.29-1.73; p < 0.0001) compared to other high-risk PCP. In the UH cohort, PSA level was found to be a significant factor for the risk of DM (HR, 1.01; 95{\%} CI, 1.001-1.02) but not OS and BF. Gleason grades of 8 to 10 were found to consistently predict for poor OS, DM, and BF outcomes (with HR estimates ranging from 1.41-2.36) in both the high-risk cohort and the UH cohort multivariable analyses. Conclusions: UH PSA levels at diagnosis are related to detrimental changes in OS, DM, and BF. All three outcomes can be modeled by various combinations of all predictive variables tested.",
keywords = "Clinical trials, External beam radiation therapy, Hormonal therapy, Outcomes, Prognostic factors, Prostate cancer",
author = "George Rodrigues and Kyounghwa Bae and MacK Roach and Colleen Lawton and Bryan Donnelly and David Grignon and Gerald Hanks and Arthur Porter and Herbert Lepor and Howard Sandler",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.ijrobp.2010.02.034",
language = "English (US)",
volume = "80",
pages = "445--452",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two radiation therapy oncology group prostate clinical trials

AU - Rodrigues, George

AU - Bae, Kyounghwa

AU - Roach, MacK

AU - Lawton, Colleen

AU - Donnelly, Bryan

AU - Grignon, David

AU - Hanks, Gerald

AU - Porter, Arthur

AU - Lepor, Herbert

AU - Sandler, Howard

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Purpose: To assess ultrahigh (UH; prostate-specific antigen [PSA] levels ≥50 ng/ml) patient outcomes by comparison to other high-risk patient outcomes and to identify outcome predictors. Methods and Materials: Prostate cancer patients (PCP) from two Phase III Radiation Therapy Oncology Group clinical trials (studies 9202 and 9413) were divided into two groups: high-risk patients with and without UH baseline PSA levels. Predictive variables included age, Gleason score, clinical T stage, Karnofsky performance score, and treatment arm. Outcomes included overall survival (OS), distant metastasis (DM), and biochemical failure (BF). Unadjusted and adjusted hazard ratios (HRs) were calculated using either the Cox or Fine and Gray's regression model with associated 95% confidence intervals (CI) and p values. Results: There were 401 patients in the UH PSA group and 1,792 patients in the non-UH PSA PCP group of a total of 2,193 high-risk PCP. PCP with UH PSA were found to have inferior OS (HR, 1.19; 95% CI, 1.02-1.39, p = 0.02), DM (HR, 1.51; 95% CI, 1.19-1.92; p = 0.0006), and BF (HR, 1.50; 95% CI, 1.29-1.73; p < 0.0001) compared to other high-risk PCP. In the UH cohort, PSA level was found to be a significant factor for the risk of DM (HR, 1.01; 95% CI, 1.001-1.02) but not OS and BF. Gleason grades of 8 to 10 were found to consistently predict for poor OS, DM, and BF outcomes (with HR estimates ranging from 1.41-2.36) in both the high-risk cohort and the UH cohort multivariable analyses. Conclusions: UH PSA levels at diagnosis are related to detrimental changes in OS, DM, and BF. All three outcomes can be modeled by various combinations of all predictive variables tested.

AB - Purpose: To assess ultrahigh (UH; prostate-specific antigen [PSA] levels ≥50 ng/ml) patient outcomes by comparison to other high-risk patient outcomes and to identify outcome predictors. Methods and Materials: Prostate cancer patients (PCP) from two Phase III Radiation Therapy Oncology Group clinical trials (studies 9202 and 9413) were divided into two groups: high-risk patients with and without UH baseline PSA levels. Predictive variables included age, Gleason score, clinical T stage, Karnofsky performance score, and treatment arm. Outcomes included overall survival (OS), distant metastasis (DM), and biochemical failure (BF). Unadjusted and adjusted hazard ratios (HRs) were calculated using either the Cox or Fine and Gray's regression model with associated 95% confidence intervals (CI) and p values. Results: There were 401 patients in the UH PSA group and 1,792 patients in the non-UH PSA PCP group of a total of 2,193 high-risk PCP. PCP with UH PSA were found to have inferior OS (HR, 1.19; 95% CI, 1.02-1.39, p = 0.02), DM (HR, 1.51; 95% CI, 1.19-1.92; p = 0.0006), and BF (HR, 1.50; 95% CI, 1.29-1.73; p < 0.0001) compared to other high-risk PCP. In the UH cohort, PSA level was found to be a significant factor for the risk of DM (HR, 1.01; 95% CI, 1.001-1.02) but not OS and BF. Gleason grades of 8 to 10 were found to consistently predict for poor OS, DM, and BF outcomes (with HR estimates ranging from 1.41-2.36) in both the high-risk cohort and the UH cohort multivariable analyses. Conclusions: UH PSA levels at diagnosis are related to detrimental changes in OS, DM, and BF. All three outcomes can be modeled by various combinations of all predictive variables tested.

KW - Clinical trials

KW - External beam radiation therapy

KW - Hormonal therapy

KW - Outcomes

KW - Prognostic factors

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=79955578017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955578017&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2010.02.034

DO - 10.1016/j.ijrobp.2010.02.034

M3 - Article

C2 - 20615632

AN - SCOPUS:79955578017

VL - 80

SP - 445

EP - 452

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -